Who
Karah Herdman Parschauer
EVP and Chief Legal Officer
Company insider
Files Form 4 as: EVP and Chief Legal Officer, Ultragenyx Pharmaceutical; Director, Tenaya Therapeutics; Director, Evolus; Director, Anebulo Pharmaceuticals; Director, Arcturus Therapeutics Holdings.
In numbers
- Trades disclosed
- 131
- Buys
- 0
- Sells
- 37
- Bought
- $0
- Sold
- $11.3M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 20 Jun 2016
- Last trade
- 3 Aug 2026
- Last filed
- 4 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Aug 2026filed 4 Aug 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $47K1,900 at $24.92 | filing |
| 3 Aug 2026filed 4 Aug 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $47K1,900 at $24.92 | filing |
| 15 Jun 2026filed 15 Jun 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $47K1,899 at $24.62 | filing |
| 15 Jun 2026filed 15 Jun 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $47K1,899 at $24.62 | filing |
| 28 May 2026filed 29 May 2026 | TNYA Tenaya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 28 May 2026filed 29 May 2026 | TNYA Tenaya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 16 Apr 2026filed 20 Apr 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —28,895 at $0.00 | filing |
| 16 Apr 2026filed 20 Apr 2026 | RARE Ultragenyx Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —49,960 at $0.00 | filing |
| 16 Apr 2026filed 20 Apr 2026 | RARE Ultragenyx Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —49,960 at $0.00 | filing |
| 16 Apr 2026filed 20 Apr 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —28,895 at $0.00 | filing |
| 10 Mar 2026filed 10 Mar 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $80K3,508 at $22.67 | filing |
| 10 Mar 2026filed 10 Mar 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $80K3,508 at $22.67 | filing |
| 6 Mar 2026filed 10 Mar 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $129K6,018 at $21.40 | filing |
| 6 Mar 2026filed 10 Mar 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $129K6,018 at $21.40 | filing |
| 2 Mar 2026filed 3 Mar 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $185K8,135 at $22.80 | filing |
| 2 Mar 2026filed 3 Mar 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $185K8,135 at $22.80 | filing |
| 1 Mar 2026filed 3 Mar 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —11,137 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —11,137 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | EOLS EvolusBiotechnology | SEC FORM 4 Code A | —45,559 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | EOLS EvolusBiotechnology | SEC FORM 4 Code A | —45,559 at $0.00 | filing |
News
Rep. Gilbert Ray Cisneros, Jr. Buys Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)RARE · themarketsdaily.com · 15 Oct 2026Ultragenyx (NASDAQ: RARE) agrees to sell PRV for $203 million in cashRARE · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Karah Herdman Parschauer; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.